Published: Thu, November 22, 2018
Health Care | By Cedric Leonard

Will Peanut Treatment Guard Against Peanut Allergy?

Will Peanut Treatment Guard Against Peanut Allergy?

After one year of treatment with a newly invented drug by Immune Therapeutics, says about 70% of children and teenagers suffering from peanut allergies were able to accept two peanuts or equivalent.

Almost 500 children aged four to 17 from across the USA and Europe took part in the trial - known as the Palisade study - making it the largest-ever peanut allergy treatment trial. At the end of the trial, Two-thirds tolerated the equivalent of two peanuts, which would provide protection against reactions to accidental peanut exposures.

The majority of the participants were between ages 4 and 17, the group in which researchers found the drug to be effective.

Professor George du Toit, paediatric allergy consultant at Evelina London and the study's chief investigator, said: "Peanut allergy is extremely hard to manage for children and their families, as they have to follow a strict peanut-free diet". Life changed for him and his family when, as a toddler, the family discovered his allergy.

In the exit challenge, only 10% of treated patients received epinephrine to treat their allergic reaction (median dose of 1,000 mg of peanut protein) compared to 53% for placebo (median dose of 100 mg).

'Families live in fear of accidental exposure as allergic reactions can be very severe, and can even lead to death.

Djokovic Beats Isner, Zverev Tops Cilic — ATP Finals
The writing was on the wall for Isner when Djokovic broke serve at 3-3 in the second set - the Serb roaring his approval. Djokovic saved it with a service victor but then double-faulted to give the 21-year-old another opportunity.

Patients suffering from a peanut allergy were given the oral drug containing a daily dose of peanut protein.

"Almost 6 million American children are now living with a life-threatening food allergy", said Ciaccio. "The goal of this treatment is to help protect people from those potentially life-threatening reactions".

By giving people with peanut allergies small amounts of peanut flour, "you're trying to desensitize them to their allergy", Alan explains.

The treatment is now awaiting FDA evaluation.

The study included 551 patients, aged 4 to 55, with peanut allergy. The agency has granted the treatment an expedited approval process, and AR101 could become available to patients by the summer of 2019. He had just completed a year-long clinical trial of an oral immunotherapy regimen that aims to reduce children's sensitivity to peanut allergens by gradually exposing them to peanut protein over the course of six months, starting with minute amounts that are carefully measured and increased incrementally under medical supervision as tolerance develops.

Like this: